Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $228.14 Average PT from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $228.1429.

A number of equities analysts have issued reports on the company. Bank of America raised their target price on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Citigroup upped their target price on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Chardan Capital boosted their price target on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Guggenheim set a $224.00 price objective on Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. Finally, HC Wainwright restated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Monday, September 15th.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $253.36 on Wednesday. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $255.00. The firm has a market capitalization of $7.35 billion, a P/E ratio of 37.99 and a beta of 0.48. The company’s 50 day simple moving average is $211.97 and its 200 day simple moving average is $172.54.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, beating the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The company had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. Sell-side analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the transaction, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 13.70% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors have recently added to or reduced their stakes in the stock. Brooklyn Investment Group increased its holdings in Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock worth $25,000 after purchasing an additional 105 shares in the last quarter. Hantz Financial Services Inc. raised its position in Krystal Biotech by 8,950.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after buying an additional 179 shares during the last quarter. Bessemer Group Inc. boosted its position in Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after acquiring an additional 77 shares during the last quarter. Twin Tree Management LP bought a new position in shares of Krystal Biotech during the 1st quarter worth approximately $29,000. Finally, AdvisorNet Financial Inc acquired a new stake in shares of Krystal Biotech in the third quarter valued at approximately $30,000. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.